Dimopoulos, M Oriol, A Nahi, H San Miguel, J Bahlis, N Rabin, N Orlowski, R Komarnicki, M Suzuki, K Plesner, T others, An open-label, randomised phase 3 study of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): POLLUX, Haematologica-the hematology journal, (101), 342, 2016,